Evaluation of Nimotuzumab (hR3) mAb as Monotherapy in patients with metastatic or recurrent colorectal cancer.
Latest Information Update: 14 Oct 2020
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 22 Dec 2013 New trial record